Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial

Hiroyoshi Nishikawa, Vincent Meininger, Pierre-François Pradat, Andrea Corse, Safa Al-Sarraj, Benjamin Rix Brooks, James B. Caress, Merit Cudkowicz, Stephen J. Kolb, Dale Lange, P. Nigel Leigh, Thomas Meyer, Stefano Milleri, Karen E. Morrison, Richard W. Orrell, Gary Peters, Jeffrey D. Rothstein, Jeremy Shefner, Arseniy Lavrov, Nicola WilliamsPhil Overend, Jeffrey Price, Stewart Bates, Jonathan Bullman, David Krull, Alienor Berges, Bams Abila, Guy Meno-Tetang, Jens Wurthner

Research output: Contribution to journalArticle

29 Citations (Scopus)
Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalPLoS ONE
Volume9
Issue number5
DOIs
Publication statusPublished - 19 May 2014

Cite this

Nishikawa, H., Meininger, V., Pradat, P-F., Corse, A., Al-Sarraj, S., Rix Brooks, B., Caress, J. B., Cudkowicz, M., Kolb, S. J., Lange, D., Leigh, P. N., Meyer, T., Milleri, S., Morrison, K. E., Orrell, R. W., Peters, G., Rothstein, J. D., Shefner, J., Lavrov, A., ... Wurthner, J. (2014). Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS ONE, 9(5), 1-12. https://doi.org/10.1371/journal.pone.0097803